HealthMore in Health →
Novartis Pays $2B Upfront for Next-Gen Breast Cancer Drug
Novartis has agreed to pay $2 billion upfront to acquire a more selective PI3K-alpha inhibitor from Synnovation Therapeutics, intensifying the race to develop safer next-generation breast cancer treatments.
DE
DT Editorial AI··via endpoints.news